Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 88/100

This clearance strictly requires NAM to be heavily methylated into N1-methylnicotinamide (MeNAM) by the enzyme nicotinamide N-methyltransferase (NNMT), a taxing process that consumes vast quantities of the body's endogenous methyl donors (primarily S-adenosylmethionine, or SAMe)44. Chronic, high-dose NAD+ precursor supplementation without a methyl donor can therefore severely deplete the systemic methyl pool. This methyl depletion leads to impaired gene methylation, disrupted neurotransmitter synthesis, and a dangerous, silent accumulation of homocysteine—an inflammatory amino acid highly correlated with lethal cardiovascular disease44. Co-supplementing with TMG provides a robust, exogenous source of methyl groups, effectively resupplying the biochemical "fuel" required for NNMT activity, ensuring the safe and rapid excretion of NAM metabolic waste, driving the re-methylation of toxic homocysteine back into safe methionine, and allowing for sustained, high-dose NMN therapy without inducing any metabolic toxicity44.

Knowledge Graph:Vector: CellularMitochondriaEpigenetic Drift
Head-to-Head CompareAudit in Stack
Cellular Energy & LongevityCellularSilver Tier85–94Moderate Confidence (Translational)⚖️ Scientific Consensus: Stable

Sublingual Micronized NMN (1g) + TMG (500mg)

Direct enzymatic NAD+ precursor paired with methyl donor TMG to fuel SIRT1/3 sirtuin enzymes and DNA repair (PARP1).

88/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

This clearance strictly requires NAM to be heavily methylated into N1-methylnicotinamide (MeNAM) by the enzyme nicotinamide N-methyltransferase (NNMT), a taxing process that consumes vast quantities of the body's endogenous methyl donors (primarily S-adenosylmethionine, or SAMe)44. Chronic, high-dose NAD+ precursor supplementation without a methyl donor can therefore severely deplete the systemic methyl pool. This methyl depletion leads to impaired gene methylation, disrupted neurotransmitter synthesis, and a dangerous, silent accumulation of homocysteine—an inflammatory amino acid highly correlated with lethal cardiovascular disease44. Co-supplementing with TMG provides a robust, exogenous source of methyl groups, effectively resupplying the biochemical "fuel" required for NNMT activity, ensuring the safe and rapid excretion of NAM metabolic waste, driving the re-methylation of toxic homocysteine back into safe methionine, and allowing for sustained, high-dose NMN therapy without inducing any metabolic toxicity44.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:33888596

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

DOUBLE BLIND RCT • Sample: N = 25

“Muscle Insulin Sensitivity (Glucose Disposal Rate): +25%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Neutral Pathway
0/ 100

No direct primary biochemical modulation of heart health; pathway is neutral for Sublingual Micronized NMN (1g) + TMG (500mg).

Brain Longevity & Cognition

Neutral Pathway
0/ 100

No direct primary biochemical modulation of brain longevity; pathway is neutral for Sublingual Micronized NMN (1g) + TMG (500mg).

Metabolic & Glycemic Health

Foundational Target (65-100)
89/ 100

Elevated mitochondrial NAD+ activates mitochondrial SIRT3 deacetylase, enhancing complex I enzymatic efficiency and fatty acid beta-oxidation in skeletal myofibers.

Hyperinsulinemic-Euglycemic Clamp Glucose Infusion RateMuscle AKT / mTOR PhosphorylationFasting Plasma FFA
NMN and Skeletal Muscle Metabolic PlasticityPMID: 33888596

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cancer defense; pathway is neutral for Sublingual Micronized NMN (1g) + TMG (500mg).

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

No direct primary biochemical modulation of testosterone; pathway is neutral for Sublingual Micronized NMN (1g) + TMG (500mg).

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

No direct primary biochemical modulation of chronic inflammation; pathway is neutral for Sublingual Micronized NMN (1g) + TMG (500mg).

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct primary biochemical modulation of bone density; pathway is neutral for Sublingual Micronized NMN (1g) + TMG (500mg).

Cellular Longevity & Epigenetics

Foundational Target (65-100)
93/ 100

Micronized nicotinamide mononucleotide directly enters cells via the Slc12a8 transporter or is converted to NR to feed the salvage pathway, regenerating the coenzyme NAD+ pool. Co-administered trimethylglycine (TMG) donates methyl groups to homocysteine, preventing methyl-donor depletion from nicotinamide N-methyltransferase (NNMT) excretion.

Whole-Blood NAD+ / NADH RatioPeripheral PBMC SIRT1 ActivitySerum Methylation Index (SAM/SAH)
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenPMID: 33888596
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Whole-Blood NAD+ Replenishment & Muscle Glucose Disposal
Secondary Clinical Endpoints:
Endothelial Nitric Oxide BioavailabilityExercise Endurance & Oxygen ConsumptionCellular PARP1 DNA Repair Efficiency
LEVL Recommended Tracking Metrics:
blood nad levelsfasting insulinexercise endurance

Cellular NAD+ Elevation

93/99
Very High EffectGrade A (Washington University Double-Blind Placebo-Controlled RCT, Science 2021)1g sublingual in the morning + 500mg TMG
NMN Human Clinical Metabolic TrialPMID: 33888596

Clinical Endpoint: Increased skeletal muscle insulin sensitivity by 25% and restored youth-like sirtuin signaling pathways in human skeletal muscle.

cellular_nad+_elevation

Physical Energy

daily wellbeing
93/99
Very High EffectGrade A (Double-Blind Multi-Arm RCT)2-4 weeks
The efficacy and safety of beta-nicotinamide mononucleotide (NMN) in healthy adults: A randomized, multicenter, double-blind clinical trialPMID: 36484374

Clinical Endpoint: Dose-dependent multi-center RCT (n=80): 600mg daily NMN produced statistically significant increases in blood NAD+ and 6-minute walking test distance (+18.4%).

physical_energy

Endurance

daily wellbeing
90/99
Very High EffectGrade A (Human Clinical RCT)4-6 weeks
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: A randomized, double-blind studyPMID: 34238308

Clinical Endpoint: Improves oxygen utilization in skeletal muscle and raises first ventilatory threshold (VT1) and power at VT2.

endurance

Metabolic Health

biological longevity
88/99
High EffectGrade A (Science Human Double-Blind RCT)6-10 weeks
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenPMID: 33888596

Clinical Endpoint: Landmark Science trial (n=25): 250mg NMN daily for 10 weeks increased skeletal muscle insulin sensitivity by ~25% and upregulated PDGF signaling.

metabolic_health

Mental Focus

daily wellbeing
85/99
High EffectGrade B (Clinical Cohort)2-4 weeks
Oral administration of NMN improves cerebral blood flow and attenuates daytime executive fatiguePMID: 35732835

Clinical Endpoint: Elevates cerebral microvascular blood flow via endothelial SIRT1 activation, relieving mental fog during sustained cognitive loading.

mental_focus
Explainable Longevity Score Decomposition

Score Breakdown: 88 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength82/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude92/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index92/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit96/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility82/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=25 pooled participants) across 82/100 evidence strength and 92/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
$30–$100 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Sublingual Micronized NMN (1g) + TMG (500mg) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
25
Avg RoB
1.3 / 5
Human Clinical (n=25)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.3

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Yoshino M, et al.•Science•2021•N = 25•10 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Muscle Insulin Sensitivity (Glucose Disposal Rate)+25%
+25%p < 0.05
Clinical Takeaway:10 weeks of 250mg NMN supplementation significantly upregulated muscle insulin sensitivity and muscle remodeling gene pathways in humans.
Independent Academic Research
PubMed: 33888596DOI
Chronological Evolution of Evidence

Sublingual Micronized NMN (1g) + TMG (500mg) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Sublingual Micronized NMN (1g) + TMG (500mg) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)